When Should You SELL Your Stocks (8 Reasons to Sell Your Stocks) Click to watch on Youtube.

Galmed Pharmaceuticals Ltd. Stock Forecast

NASDAQ:GLMD BUY

$0.47 (5.71%)

Volume: 176.686k

Closed: Aug 16, 2022

Hollow Logo Score: -2.923

Galmed Pharmaceuticals Ltd. Stock Forecast

BUY NASDAQ:GLMD
$0.47 (5.71%)

Volume: 176.686k

Closed: Aug 16, 2022

Score Hollow Logo -2.923

GLMD Price Targets and Analyst Ratings NASDAQ:GLMD

GLMD Forecast. What You Should Know.

GLMD Historical Ratings and Targets

FAQ

What are analyst ratings?
Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts. Read More...

What to keep in mind using analyst ratings?
The best way to use analyst ratings is to supplement your investment research. Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Also, be sure to pay attention to the date of the rating. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Read More...

What is a price target in trading?
A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company's earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate. However, it can guide investors looking to buy or sell a stock. Read More...

Unlock All Premium Features! Go Premium! Only $19.90/Month

Unlock the Top 5 candidates in every list
Unlock full Ultimate List Builder
Golden Star lists & Auto Portfolios
Possible Runners & Moving Average lists
Ad-free browsing
Save data in PDF

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... Read more

.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT